About Cipla Biotec
Cipla Biotec is a company based in India founded in 2008 was acquired by Cipla in June 2014. The company has 28 employees as of April 07, 2024. Cipla Biotec operates in a competitive market with competitors including Zymeworks, Xilio Therapeutics, Harbour BioMed, Ambrx and Lassen Therapeutics, among others.
- Headquarter Salcete, India
- Employees 28 as on 07 Apr, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cipla Pharma And Life Sciences Limited
- Date of Incorporation 20 Aug, 2008
- Jurisdiction Mumbai, Maharashtra, India
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cipla Biotec
Detailed funding history for Cipla Biotec
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cipla Biotec
Cipla Biotec has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cipla.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
APIs, generic drugs, and formulation services are manufactured.
|
Locked | Locked | Locked |
Investor details for Cipla Biotec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cipla Biotec
Investment portfolio details for Cipla Biotec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cipla Biotec
Detailed financials for Cipla Biotec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cipla Biotec Comparisons
Peer comparison for Cipla Biotec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cipla Biotec
Cipla Biotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zymeworks, Xilio Therapeutics, Harbour BioMed, Ambrx and Lassen Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Tumor-selective immunotherapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Antibody therapeutics are developed for immunology and oncology diseases.
|
|
| Locked | Locked | Locked |
Antibody-drug conjugates are developed for cancers and metabolic disorders.
|
|
| Locked | Locked | Locked |
Biotherapeutics targeting cancer via interleukin-11 are developed.
|
|
| Locked | Locked | Locked |
Novel immuno-oncology therapeutics are acquired and developed for clinical advancement.
|
Detailed competitors of Cipla Biotec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cipla Biotec
Complete news archive for Cipla Biotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cipla Biotec
Cipla Biotec was founded in 2008.
Cipla Biotec is headquartered in India. It is registered at Goa, India.
As of Apr 07, 2024, the latest employee count at Cipla Biotec is 28.
Annual revenue of Cipla Biotec is $2.16M as on Mar 31, 2023.
Cipla Biotec (formerly mabpharm) develops monoclonal antibodies and peptide hormones for treatment of cancers, diabetes and Wet Age-Related Macular Degeneration. Its lead product CBT 124, a monoclonal antibody angiogenesis inhibitor which targets multiple cancers is currently under pre-clinical study. Its other products include CBT 125, a peptide hormone which got approval in India to treat diabetes; CBT 127 (mAb) for breast cancer in the development phase and CBT 128 (mAb) for Wet Age-Related Macular Degeneration in the pre-clinical study. On July 17, 2014 Ciplas unit Meditab Specialities acquired Mabpharm and since then serving as a wholly subsidiary unit of Cipla.
Cipla Biotec's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
Cipla Biotec has 1 investor. Key investors include Cipla.